Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast in systemic sclerosis (double-blind, randomized, placebo-controlled)
jRCT2031260339Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in systemic sclerosis (SSc) comparing Nerandomilast with Placebo (2 arms). Primary endpoint: Time to first occurrence of disease progression or all-cause death. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
nerandomilast
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on jRCT2031260339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260339.